TFAM and neoplasm: Our results provide evidence of a negative correlation between miR-181a/b expression and their target TFAM in patients with a positive outcome and responding to targeted therapies (Figure 6), thus strongly suggesting that miR-181a/b exert their tumor-suppressive action by targeting TFAM and thus silencing its pro-tumorigenic functions.